Viatris’ Glatiramer Acetate Injection is an AP-rated therapeutic equivalent to COPAXONE®.
While refrigeration is preferred, when you are not able to refrigerate Glatiramer Acetate Injection you may store it for up to 1 month at room temperature between 15° to 30°C (59° to 86°F).
What Is Glatiramer Acetate?
Glatiramer Acetate is a prescription medication that can be injected subcutaneously to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Every dose of Glatiramer Acetate is composed of a complex mixture of polypeptides containing four naturally occurring amino acids.1,2
Some scientists think that MS may result when the body's immune system attacks the sheath that surrounds and protects nerve cell axons.1 Although the mechanism of action of Glatiramer Acetate is not fully known, there is evidence that it may help reduce MS relapses by interrupting this immune system attack.1
What is Glatiramer Acetate Injection?
Glatiramer Acetate Injection is a clear, colorless to slightly yellow, sterile, nonpyrogenic solution in a 1 mL single-dose prefilled syringe with fixed ½ inch 29 gauge needle supplied as:
This means that Glatiramer Acetate Injection may be substituted for the equivalent dose of COPAXONE and may be expected to have a comparable safety and efficacy profile.2
Like COPAXONE, Glatiramer Acetate Injection is available by prescription only, for injection under the skin.3
A Complex Drug, But Not a Biologic
According to the FDA, a biologic is a protein derived from living material used to treat or cure disease. Because the polypeptides that make up Glatiramer Acetate are manufactured in the lab, it is not classified as a biologic.4
The mechanism(s) by which Glatiramer Acetate exerts its effects in patients with MS are not fully understood. Glatiramer Acetate is a mixture of synthetic polypeptides composed of four amino acids. Given subcutaneously, Glatiramer Acetate is readily absorbed, and most of a dose is quickly degraded into smaller fragments in the subcutaneous department. Glatiramer Acetate is believed to induce the regulatory cells that inhibit the immunological damage process that occurs in MS.